QUIZARTINIB ALLOWS TO BUY TIME BEFORE TRANSPLANT IN AML.
In AML patient with FLT3-ITD
46% complete response reported
27% partial response
--------------------------------------
73% total response rate per this account

IF you do not have the FLT3-ITD
32% CR
16% PR
----------------------------------
48% RR

Median duration of response 3 months for FLT3 positive
and 1.5 month for FLT3 negative

the drug is reported to be well tolerated.

*> In other Major news,
Eribulin had failed to best Xeloda overall
there was a positive trend  in triple negative breast cancer which is the focus of CRBCM

*Apixaban may become a valid option for DVT treatment
since it does not require monitoring
and it is not cleared by the Kidneys and therefore could be used in kidney failure patients!